ClinicalTrials.gg
RecruitingNCT06630793IMPACUpdated Apr 8, 2025

IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer

An interventional study of IMPT (Intensity Modulated Proton Therapy) and IMRT (Intensity Modulated Radiation Therapy) in Malignant Neoplasm of Anal Canal, sponsored by Tata Memorial Centre. Recruiting at 1 site in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Tata Memorial Centre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The standard practice in management of carcinoma of anal canal is to treat patients with radiotherapy using the IMRT technique along with chemotherapy. It is known that while IMRT has reduced treatment related side effects as compared to the older radiation techniques, reducing these side effects further still remains a major challenge.

These side-effects include gastrointestinal (diarrhea, altered bowel habits, weight loss, bleeding, obstruction), genitourinary (difficulties in passing urine, passing blood in urine, difficulty in holding urine) and hematologic toxicities (anemia, low platelet count and increased predisposition to infections).

Proton therapy (IMPT) is a form of radiation treatment in which high doses can be delivered within the tumor while the surrounding normal tissues receive a lesser radiation dose. It is believed that these physical properties of proton therapy may help reduce the side effects of treatment.

Patients will be randomly assigned to either receive IMRT or IMPT based treatment so as to see whether it is possible to reduce the acute treatment related toxicities. In this study, there is a 66.7% chance that the patient will get IMPT based treatment, which may be able to reduce the toxicities.

02

Conditions studied

  • Malignant Neoplasm of Anal Canal

Browse trials for

Keywords

  • IMPT
  • IMRT
  • Anal canal
03

In context

Anal Canal Carcinoma

33 studies on the registry are indexed under Anal Canal Carcinoma; 8 are open to participants now.

This study's planned enrollment of 108 is above the median of 67 across 30 interventional studies indexed under Anal Canal Carcinoma.

Browse Anal Canal Carcinoma studies →

Lead sponsor

Tata Memorial Centre is the lead sponsor of 64 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 18 and \< 80 years of age
  2. confirmed squamous cell carcinoma of the anal canal or distal rectum
  3. The patients may have TNM stage T1-2 N+M0 or T3-4 N0-1c M0 (UICC 8th edition)
  4. Involvement of lower para-aortic lymph nodes (till renal hilum) as the only site of disease extension on PET CECT may also be included as they receive radical chemoradiation as standard treatment.
  5. WHO or performance status 0-1
  6. testing is known and HPV (P16) testing done on tissue sample.
  7. With suitable blood test values for standard concurrent chemotherapy ( > 10 mg/dL, > 1.5 cells/mm3, > 100,000 cells/mm3, Creatinine \< 1.5 x , \< 3 x ULN, \< 3 x ULN) as deemed by a medical oncologist in team.
  8. The patient must be expected to tolerate the treatment and be compliant for follow up.
  9. No contradiction for chemoradiation such as inflammatory bowel disease, pregnancy, etc.
  10. Willing to consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Two or more synchronous primary cancers.
  2. When prosthetic materials (e.g. hip prostheses) are present close to the target volume, it must be considered if this may introduce uncertainties in dose calculations, which may affect the treatment planning process.
  3. Ulcerative colitis or any other confirmed inflammatory bowel disease.
  4. Poor reliability for follow-up and treatment completion.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Radical CTRT with IMPT (Intensity Modulated Proton Therapy)

    Patients randomized to proton therapy arm will receive radiotherapy with IMPT technique along with concurrent chemotherapy for a duration 6-8 weeks.

    Radiation: IMPT (Intensity Modulated Proton Therapy)

  • Active comparator
    Radical CTRT with IMRT (Intensity Modulated Radiation Therapy)

    Patients randomized to photon arm will receive radiotherapy with IMRT technique along with concurrent chemotherapy for a duration 6-8 weeks.

    Radiation: IMRT (Intensity Modulated Radiation Therapy)

Interventions

  • RadiationIMPT (Intensity Modulated Proton Therapy)

    Proton therapy is a form of radiation treatment in which high doses can be delivered within the tumour while relatively sparing the surrounding normal tissues. This may help further reduce the side-effects of radiation treatment observed with IMRT.

  • RadiationIMRT (Intensity Modulated Radiation Therapy)

    The standard management of carcinoma of the anal canal is radiotherapy using the IMRT technique along with concurrent chemotherapy. The use of IMRT has reduced the treatment-related side-effects as compared to older radiation techniques. However, further reducing these side effects poses a major challenge.

06

What researchers measure

Primary outcomes

  1. Grade 3 or higher acute toxicity

    The highest GI/GU/Hematological toxicity will be captured per patient will be documented using CTCAE v5.0 and the percentage of patients with more than Grade 3 toxicity will be added in each arm and compared proportionately.

    Time frame: Upto 6 months post-last cytotoxic therapy.

Secondary outcomes

  1. Local Failure

    Local control will be computed as the time between randomization and local relapse or progression, Measurable persistent disease after six months from the completion of chemoradiation therapy will be considered a local failure.

    Time frame: 5 years since randomization

  2. Regional Failure

    From randomisation till a situation in which a patient who initially had no signs of disease in the pelvic and groin nodes later displays disease in these nodes after receiving treatment or reappearance of the disease in these nodes after they were initially cleared or the presence of persistent nodal disease for more than six months after completing the treatment.

    Time frame: 5 years since randomization

  3. Distant Relapse

    The rate of relapse of the tumor outside the pelvic region.

    Time frame: 5 years since randomization

  4. Colostomy-free Survival

    From the the time of randomization till the necessity for colostomy is clinically warranted or death due to any cause.

    Time frame: 5 years since randomization

  5. Disease-free Survival

    The time from randomization to local or regional or distant recurrence of tumor or death

    Time frame: 5 years since randomization

  6. Overall Survival

    From randomisation till anal cancer or treatment-related death.

    Time frame: 5 years since randomization

  7. Treatment-related late toxicities

    After 3 months of treatment and up to 5 years or death due to any cause, will be documented using CTCAE v5.0

    Time frame: 5 years since randomization

  8. Patient-Reported Health-Related Quality of Life QLQ-C30 questionnaires

    Will be assessed using Health Related Quality of Life questionnaires (QLQ) of European Organization for Research and Treatment of Cancer (EORTC)

    Time frame: 5 years since randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Nov 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2024
First posted
Oct 8, 2024
StartActual
Mar 18, 2025
Primary completionEst.
Nov 1, 2027
CompletionEst.
May 1, 2032
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06630793
Lead sponsor
Tata Memorial Centre
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
Mar 18, 2025
Primary completion
Nov 1, 2027 (estimated)
Completion
May 1, 2032 (estimated)
Last update
Apr 8, 2025

Study contacts

Dr Rahul Krishanatry, MD
Contact
krishnatry@gmail.com
02224177028 ext. 7028
Dr Rahul Krishanatry, MD
Contact
krishanatry@gmail.com
02224177028 ext. 7028

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion